Want to see SE:IMMU full AI Analyst Report?
Top Page
Immunicum AB
(IMMU)
Select Model
Select Model
Rating:48Neutral
Price Target:
kr6.50
▲(12.65% Upside)
Action:Reiterated
Date:08/21/26
The score is primarily held back by weak financial performance—persistent losses, lack of recurring revenue, and ongoing cash burn—despite low leverage on the balance sheet. Technical indicators add moderate support with a generally positive trend versus key moving averages and neutral momentum, while valuation remains constrained by negative earnings and no dividend yield data.
Positive Factors
Low Financial Leverage
Very low leverage limits fixed financial obligations and preserves flexibility for research spending or future financing. This is a relative strength for a clinical-stage biotech, although it does not offset the company’s lack of operating income.
Negative Factors
No Recurring Revenue Base
The absence of recurring revenue leaves the company dependent on external financing or potential collaboration payments. Without a reliable commercial income stream, operating costs cannot currently be absorbed by the business itself.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Very low leverage limits fixed financial obligations and preserves flexibility for research spending or future financing. This is a relative strength for a clinical-stage biotech, although it does not offset the company’s lack of operating income.
Read all positive factors
Immunicum AB (IMMU) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr466.87M
Dividend YieldN/A
Average Volume (3M)23.03K
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue GrowthN/A
EPS Growth15.97%
CountrySE
Employees19
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.79
Shares Outstanding64,784,580
10 Day Avg. Volume26,663
30 Day Avg. Volume23,034
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.46
Revenue Forecast (FY)kr5.00M
Immunicum AB Business Overview & Revenue Model
Company Description
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compou...
How the Company Makes Money
Immunicum AB has historically not had recurring revenue from marketed products; as a clinical-stage biotechnology company, its ability to generate operating income has primarily depended on external financing and, where applicable, collaboration-r...
Immunicum AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 28.49M | 3.00M | 6.00K |
| Gross Profit | -4.55M | -6.29M | -6.52M | 28.49M | -1.85M | -1.84M |
| EBITDA | -106.50M | -113.97M | -120.66M | -97.85M | -128.67M | -128.28M |
| Net Income | -102.49M | -113.26M | -128.40M | -101.62M | -136.99M | -136.69M |
Balance Sheet | ||||||
| Total Assets | 621.67M | 628.32M | 696.36M | 755.95M | 620.39M | 720.98M |
| Cash, Cash Equivalents and Short-Term Investments | 59.88M | 64.66M | 101.91M | 120.78M | 41.85M | 155.31M |
| Total Debt | 17.93M | 18.85M | 22.71M | 24.49M | 78.16M | 36.98M |
| Total Liabilities | 76.38M | 43.26M | 51.22M | 51.23M | 105.95M | 64.24M |
| Stockholders Equity | 545.29M | 585.07M | 645.15M | 704.73M | 514.44M | 656.74M |
Cash Flow | ||||||
| Free Cash Flow | -74.54M | -81.84M | -81.51M | -164.58M | -121.43M | -139.39M |
| Operating Cash Flow | -73.93M | -81.53M | -79.67M | -162.76M | -109.33M | -138.03M |
| Investing Cash Flow | 196.00K | -734.00K | -1.58M | -442.00K | -12.32M | -1.36M |
| Financing Cash Flow | 74.45M | 45.18M | 61.52M | 242.10M | 8.19M | 127.03M |
Immunicum AB Technical Analysis
Positive
5.77
Price Trends
6.66
Positive
6.06
Positive
5.54
Positive
Market Momentum
0.19
Negative
63.87
Neutral
34.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IMMU, the sentiment is Positive. The current price of 5.77 is below the 20-day moving average (MA) of 6.94, below the 50-day MA of 6.66, and above the 200-day MA of 5.54, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 63.87 is Neutral, neither overbought nor oversold. The STOCH value of 34.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IMMU.
Immunicum AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr497.63M | 2.60 | 63.09% | ― | ― | ― | |
53 Neutral | kr678.44M | -2.28 | ― | ― | 87.23% | 35.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr466.87M | -4.11 | -18.05% | ― | ― | 15.97% | |
48 Neutral | kr192.20M | -8.14 | -56.09% | ― | ― | 14.10% | |
43 Neutral | kr1.60B | -3.22 | -99.58% | ― | -87.22% | -70.29% | |
40 Underperform | kr172.73M | -0.02 | -736.08% | ― | -98.81% | 80.33% |
* Healthcare Sector Average
SE:IMMU
Immunicum AB
7.36
0.46
6.67%
SE:ATORX
Alligator Bioscience AB
0.03
-0.91
-97.32%
SE:BINV
BioInvent International AB
24.30
-5.10
-17.35%
SE:ONCO
Oncopeptides AB
1.78
-3.17
-64.06%
SE:ELIC
Elicera Therapeutics AB
2.88
-3.78
-56.78%
SE:CANTA
Cantargia AB
1.77
-0.83
-31.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.